Robeco Institutional Asset Management B.V. Acquires 6,211 Shares of Boston Scientific Co. (NYSE:BSX)


Share on StockTwits

Robeco Institutional Asset Management B.V. grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 6.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 107,847 shares of the medical equipment provider’s stock after buying an additional 6,211 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Boston Scientific were worth $4,169,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the business. Strs Ohio raised its position in Boston Scientific by 3.0% in the 1st quarter. Strs Ohio now owns 1,309,956 shares of the medical equipment provider’s stock valued at $50,629,000 after buying an additional 37,743 shares during the last quarter. Heritage Investors Management Corp boosted its position in shares of Boston Scientific by 4.8% during the 1st quarter. Heritage Investors Management Corp now owns 233,263 shares of the medical equipment provider’s stock valued at $9,016,000 after acquiring an additional 10,710 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its position in shares of Boston Scientific by 67.1% during the 1st quarter. Foster Victor Wealth Advisors LLC now owns 80,760 shares of the medical equipment provider’s stock valued at $3,183,000 after acquiring an additional 32,442 shares during the last quarter. Parthenon LLC boosted its position in shares of Boston Scientific by 11.1% during the 1st quarter. Parthenon LLC now owns 13,133 shares of the medical equipment provider’s stock valued at $508,000 after acquiring an additional 1,312 shares during the last quarter. Finally, Tufton Capital Management bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $369,000. Hedge funds and other institutional investors own 90.70% of the company’s stock.

In related news, EVP Arthur C. Butcher sold 9,676 shares of the firm’s stock in a transaction that occurred on Thursday, April 15th. The stock was sold at an average price of $40.00, for a total transaction of $387,040.00. Following the completion of the sale, the executive vice president now directly owns 39,074 shares of the company’s stock, valued at approximately $1,562,960. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 48,439 shares of the firm’s stock in a transaction that occurred on Wednesday, April 28th. The stock was sold at an average price of $43.98, for a total value of $2,130,347.22. Following the sale, the executive vice president now directly owns 187,597 shares of the company’s stock, valued at $8,250,516.06. The disclosure for this sale can be found here. Insiders sold a total of 107,637 shares of company stock valued at $4,460,233 over the last ninety days. Corporate insiders own 0.70% of the company’s stock.

NYSE:BSX opened at $43.63 on Tuesday. The stock has a 50-day moving average price of $39.99 and a 200 day moving average price of $37.29. Boston Scientific Co. has a 12-month low of $32.99 and a 12-month high of $44.63. The stock has a market capitalization of $61.98 billion, a P/E ratio of 16.72, a P/E/G ratio of 2.30 and a beta of 0.87. The company has a current ratio of 1.87, a quick ratio of 1.42 and a debt-to-equity ratio of 0.60.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Tuesday, April 27th. The medical equipment provider reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The business had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.62 billion. Boston Scientific had a return on equity of 11.77% and a net margin of 36.59%. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the company earned $0.28 EPS. On average, research analysts predict that Boston Scientific Co. will post 1.05 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “hold” rating and set a $41.00 price target for the company in a research report on Tuesday, April 6th. TheStreet downgraded Boston Scientific from a “b-” rating to a “c” rating in a research report on Tuesday, March 16th. Wells Fargo & Company boosted their target price on Boston Scientific from $42.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, April 29th. Deutsche Bank Aktiengesellschaft boosted their target price on Boston Scientific from $39.00 to $45.00 and gave the stock a “hold” rating in a research report on Thursday, April 29th. Finally, Truist boosted their target price on Boston Scientific from $42.00 to $50.00 in a research report on Thursday, April 29th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $46.00.

Boston Scientific Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Further Reading: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.